Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

The company's financial results should remain strong for a while. Analysts expect earnings per share (EPS) to grow at an ...

As more Big Pharma companies have launched direct-to-consumer telehealth platforms, lawmakers have raised concerns they might ...

A new Alzheimer’s treatment from US firm Eli Lilly was approved for use this week by the UK drug regulator MHRA, although disappointingly for its maker, the drug won’t be available on the NHS as it ...

Global Gene Therapy in CNS Disorder IndustryThe global gene therapy market for central nervous system (CNS) disorders is set ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...

On 23 October 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly’s anti-amyloid beta (Aβ ...

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

Semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in people with type 2 diabetes, ...